Annual Working Capital
$633.93 M
+$25.71 M+4.23%
31 December 2023
Summary:
Halozyme Therapeutics annual working capital is currently $633.93 million, with the most recent change of +$25.71 million (+4.23%) on 31 December 2023. During the last 3 years, it has risen by +$500.55 million (+375.28%). HALO annual working capital is now -21.65% below its all-time high of $809.14 million, reached on 31 December 2021.HALO Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Working Capital
$1.02 B
+$163.72 M+19.16%
30 September 2024
Summary:
Halozyme Therapeutics quarterly working capital is currently $1.02 billion, with the most recent change of +$163.72 million (+19.16%) on 30 September 2024. Over the past year, it has increased by +$254.34 million (+33.30%). HALO quarterly working capital is now at all-time high.HALO Quarterly Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Working Capital Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +4.2% | +33.3% |
| 3 y3 years | +375.3% | +12.6% |
| 5 y5 years | +127.6% | +335.1% |
HALO Working Capital High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -21.6% | +375.3% | at high | +197.3% |
| 5 y | 5 years | -21.6% | +375.3% | at high | +663.4% |
| alltime | all time | -21.6% | >+9999.0% | at high | >+9999.0% |
Halozyme Therapeutics Working Capital History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.02 B(+19.2%) |
| June 2024 | - | $854.44 M(+15.2%) |
| Mar 2024 | - | $741.95 M(+17.0%) |
| Dec 2023 | $633.93 M(+4.2%) | $633.93 M(-17.0%) |
| Sept 2023 | - | $763.82 M(+17.6%) |
| June 2023 | - | $649.35 M(+24.1%) |
| Mar 2023 | - | $523.10 M(-14.0%) |
| Dec 2022 | $608.22 M(-24.8%) | $608.22 M(+11.8%) |
| Sept 2022 | - | $543.82 M(+58.8%) |
| June 2022 | - | $342.43 M(-61.0%) |
| Mar 2022 | - | $877.00 M(+8.4%) |
| Dec 2021 | $809.14 M(+506.6%) | $809.14 M(-10.5%) |
| Sept 2021 | - | $904.15 M(+2.1%) |
| June 2021 | - | $885.50 M(+6.1%) |
| Mar 2021 | - | $834.30 M(+525.5%) |
| Dec 2020 | $133.38 M(-70.9%) | $133.38 M(-71.7%) |
| Sept 2020 | - | $471.92 M(-0.5%) |
| June 2020 | - | $474.29 M(+11.3%) |
| Mar 2020 | - | $425.97 M(-7.0%) |
| Dec 2019 | $457.80 M(+64.4%) | $457.80 M(+95.6%) |
| Sept 2019 | - | $234.00 M(-8.7%) |
| June 2019 | - | $256.29 M(-5.2%) |
| Mar 2019 | - | $270.37 M(-2.9%) |
| Dec 2018 | $278.49 M(-26.5%) | $278.49 M(-4.2%) |
| Sept 2018 | - | $290.81 M(-11.8%) |
| June 2018 | - | $329.60 M(-9.8%) |
| Mar 2018 | - | $365.25 M(-3.6%) |
| Dec 2017 | $379.04 M(+87.7%) | $379.04 M(+50.8%) |
| Sept 2017 | - | $251.30 M(-2.7%) |
| June 2017 | - | $258.22 M(+60.7%) |
| Mar 2017 | - | $160.65 M(-20.5%) |
| Dec 2016 | $201.95 M(+84.7%) | $201.95 M(-8.2%) |
| Sept 2016 | - | $219.94 M(-10.4%) |
| June 2016 | - | $245.46 M(+5.4%) |
| Mar 2016 | - | $232.81 M(+113.0%) |
| Dec 2015 | $109.31 M(-20.2%) | $109.31 M(+1.0%) |
| Sept 2015 | - | $108.24 M(-18.9%) |
| June 2015 | - | $133.40 M(+4.9%) |
| Mar 2015 | - | $127.12 M(-7.2%) |
| Dec 2014 | $136.99 M(+94.9%) | $136.99 M(+10.5%) |
| Sept 2014 | - | $124.01 M(-13.8%) |
| June 2014 | - | $143.90 M(-6.9%) |
| Mar 2014 | - | $154.55 M(+119.9%) |
| Dec 2013 | $70.29 M | $70.29 M(+11.2%) |
| Sept 2013 | - | $63.19 M(-6.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2013 | - | $67.59 M(-26.0%) |
| Mar 2013 | - | $91.36 M(-18.2%) |
| Dec 2012 | $111.68 M(+139.2%) | $111.68 M(+32.0%) |
| Sept 2012 | - | $84.58 M(-18.3%) |
| June 2012 | - | $103.58 M(-10.6%) |
| Mar 2012 | - | $115.89 M(+148.2%) |
| Dec 2011 | $46.69 M(-37.0%) | $46.69 M(-26.1%) |
| Sept 2011 | - | $63.18 M(+11.9%) |
| June 2011 | - | $56.47 M(-15.2%) |
| Mar 2011 | - | $66.59 M(-10.2%) |
| Dec 2010 | $74.16 M(+23.5%) | $74.16 M(-14.4%) |
| Sept 2010 | - | $86.65 M(+126.5%) |
| June 2010 | - | $38.26 M(-21.8%) |
| Mar 2010 | - | $48.92 M(-18.5%) |
| Dec 2009 | $60.04 M(+0.4%) | $60.04 M(-11.2%) |
| Sept 2009 | - | $67.59 M(-13.9%) |
| June 2009 | - | $78.48 M(+48.5%) |
| Mar 2009 | - | $52.85 M(-11.6%) |
| Dec 2008 | $59.79 M(-35.2%) | $59.79 M(-11.0%) |
| Sept 2008 | - | $67.17 M(-12.4%) |
| June 2008 | - | $76.71 M(-11.8%) |
| Mar 2008 | - | $87.02 M(-5.7%) |
| Dec 2007 | $92.31 M(+123.3%) | $92.31 M(-7.5%) |
| Sept 2007 | - | $99.81 M(+3.0%) |
| June 2007 | - | $96.94 M(+42.3%) |
| Mar 2007 | - | $68.14 M(+64.8%) |
| Dec 2006 | $41.34 M(+132.2%) | $41.34 M(+183.7%) |
| Sept 2006 | - | $14.57 M(+3.9%) |
| June 2006 | - | $14.03 M(-11.7%) |
| Mar 2006 | - | $15.89 M(-10.8%) |
| Dec 2005 | $17.80 M(+22.2%) | $17.80 M(+247.3%) |
| Sept 2005 | - | $5.13 M(-42.0%) |
| June 2005 | - | $8.83 M(-24.0%) |
| Mar 2005 | - | $11.61 M(-20.3%) |
| Dec 2004 | $14.57 M(>+9900.0%) | $14.57 M(+799.5%) |
| Sept 2004 | - | $1.62 M(-65.8%) |
| June 2004 | - | $4.73 M(-30.3%) |
| Mar 2004 | - | $6.80 M(>+9900.0%) |
| Sept 2003 | - | $60.90 K(-10.2%) |
| June 2003 | - | $67.80 K(-12.5%) |
| Mar 2003 | - | $77.50 K(-27.7%) |
| Sept 2002 | - | $107.20 K(-10.1%) |
| June 2002 | - | $119.20 K(+263.4%) |
| Mar 2002 | - | $32.80 K |
| Dec 2001 | $22.80 K | - |
FAQ
- What is Halozyme Therapeutics annual working capital?
- What is the all time high annual working capital for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual working capital year-on-year change?
- What is Halozyme Therapeutics quarterly working capital?
- What is the all time high quarterly working capital for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly working capital year-on-year change?
What is Halozyme Therapeutics annual working capital?
The current annual working capital of HALO is $633.93 M
What is the all time high annual working capital for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual working capital is $809.14 M
What is Halozyme Therapeutics annual working capital year-on-year change?
Over the past year, HALO annual working capital has changed by +$25.71 M (+4.23%)
What is Halozyme Therapeutics quarterly working capital?
The current quarterly working capital of HALO is $1.02 B
What is the all time high quarterly working capital for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly working capital is $1.02 B
What is Halozyme Therapeutics quarterly working capital year-on-year change?
Over the past year, HALO quarterly working capital has changed by +$254.34 M (+33.30%)